LNAI · Lunai Bioworks Inc.
$2.12
-0.12 (-5.36%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$81.25M
Shares
36.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.24
Open$2.22
Day$2.22–2.31
52W$1.21–28.00
Avg vol 30d1.7M
Short int122K · 0.3% float · 2.6d
Short vol40%
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−57%
below
Price vs 50-day avg
−20%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−30%
trailing
6-month return
−63%
trailing
YTD return
−68%
this year
Relative strength
−71%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+22% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.34% of float · ▼ -18.9% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — 13F breadth
Squeeze score
34
low risk · 0–100
Fundamentals
EPS growth
−19%
Y/Y
Free cash flow
$-7.9M
Balance sheet
$10.2K
net debt
Quant / Vol
risk profile
Volatility
225%
annualized · 1-yr
Max drawdown
−94%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−57%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+22% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.34% of float · ▼ -18.9% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $1
Now $2 · 4%
52-wk high $28
vs 200-day avg -57%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LNAI
this stock
Lunai Bioworks Inc.
|
$81.25M | -68.3% | — | — | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LNAI | -15.2% | -30.2% | -63.1% | -31.5% | -68.3% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -14.2% | -30.2% | -70.5% | -30.7% | -76.9% |